1. Home
  2. URGN vs BGS Comparison

URGN vs BGS Comparison

Compare URGN & BGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • BGS
  • Stock Information
  • Founded
  • URGN 2004
  • BGS 1996
  • Country
  • URGN United States
  • BGS United States
  • Employees
  • URGN N/A
  • BGS N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • BGS Packaged Foods
  • Sector
  • URGN Health Care
  • BGS Consumer Staples
  • Exchange
  • URGN Nasdaq
  • BGS Nasdaq
  • Market Cap
  • URGN 547.1M
  • BGS 524.1M
  • IPO Year
  • URGN 2017
  • BGS N/A
  • Fundamental
  • Price
  • URGN $11.33
  • BGS $7.75
  • Analyst Decision
  • URGN Strong Buy
  • BGS Hold
  • Analyst Count
  • URGN 5
  • BGS 5
  • Target Price
  • URGN $44.50
  • BGS $8.30
  • AVG Volume (30 Days)
  • URGN 351.4K
  • BGS 1.6M
  • Earning Date
  • URGN 11-06-2024
  • BGS 11-05-2024
  • Dividend Yield
  • URGN N/A
  • BGS 9.89%
  • EPS Growth
  • URGN N/A
  • BGS N/A
  • EPS
  • URGN N/A
  • BGS N/A
  • Revenue
  • URGN $89,363,000.00
  • BGS $1,959,014,000.00
  • Revenue This Year
  • URGN $13.39
  • BGS N/A
  • Revenue Next Year
  • URGN $45.06
  • BGS N/A
  • P/E Ratio
  • URGN N/A
  • BGS N/A
  • Revenue Growth
  • URGN 15.64
  • BGS N/A
  • 52 Week Low
  • URGN $10.60
  • BGS $6.12
  • 52 Week High
  • URGN $20.70
  • BGS $11.97
  • Technical
  • Relative Strength Index (RSI)
  • URGN 37.97
  • BGS 60.96
  • Support Level
  • URGN $11.10
  • BGS $6.41
  • Resistance Level
  • URGN $13.13
  • BGS $7.78
  • Average True Range (ATR)
  • URGN 0.53
  • BGS 0.33
  • MACD
  • URGN -0.10
  • BGS 0.16
  • Stochastic Oscillator
  • URGN 12.15
  • BGS 79.29

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About BGS B&G Foods Inc.

B&G Foods Inc is an American packaged-food manufacturer. It operate in a single industry segment and manufacture, sell and distribute a diverse portfolio of high-quality shelf-stable and frozen foods across the United States, Canada and Puerto Rico. Its products include frozen and canned vegetables, vegetable, canola and other cooking oils, vegetable shortening, cooking sprays, oatmeal and other hot cereals, fruit spreads, canned meats and beans, bagel chips, spices, seasonings, hot sauces, wine vinegar, The company's main brands are Ac'cent, B&G, B&M, Baker's Joy, Bear Creek Country Kitchens, Cary's, Cream of Rice, Cream of Wheat, Devonsheer, Don Pepino, Durkee, Emeril's, Grandma's Molasses, MacDonald's.

Share on Social Networks: